The aim of this study was to investigate if a combination of enzalutamide and the small molecule STAT3 inhibitor GPB730 can enhance the therapeutic effect of enzalutamide in advanced prostate cancer. The gene discussed is STAT3; the disease is Familial prostate cancer.